Cardiol Therapeutics (CRDL, Financial) has attracted attention from financial analysts following its recent coverage initiation by HC Wainwright & Co. on June 2, 2025. The reputable firm has introduced a 'Buy' rating for the stock, signifying a positive outlook on the company's potential growth and performance in the market.
The analyst, Brandon Folkes, set a price target of $9.00 USD for Cardiol Therapeutics (CRDL, Financial). This target reflects the firm's expectations for the stock's value over the foreseeable future, based on current market conditions and the company's strategic initiatives.
The initiation by HC Wainwright & Co. positions Cardiol Therapeutics (CRDL, Financial) as a prominent player on the NASDAQ exchange, drawing investor interest with its promising developments. The coverage is anticipated to influence investor sentiment positively, with the stock now backed by expert analysis and a defined growth target.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 1 analysts, the average target price for Cardiol Therapeutics Inc (CRDL, Financial) is $10.07 with a high estimate of $10.07 and a low estimate of $10.07. The average target implies an upside of 705.33% from the current price of $1.25. More detailed estimate data can be found on the Cardiol Therapeutics Inc (CRDL) Forecast page.
Based on the consensus recommendation from 3 brokerage firms, Cardiol Therapeutics Inc's (CRDL, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
